ATE26464T1 - Rekombinante monoklonale antikoerper. - Google Patents

Rekombinante monoklonale antikoerper.

Info

Publication number: ATE26464T1
Authority: AT; Austria
Prior art keywords: monoclonal antibodies; recombinant monoclonal; hybridoma; trioma; lymphocyte
Prior art date: 1981-07-01

Application number

AT82303197T

Other languages

German (de)

English (en)

Inventor

Christopher L Reading

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-01

Filing date

1982-06-18

Publication date

1987-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23068220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE26464(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1982-06-18 Application filed by Univ Texas filed Critical Univ Texas

1987-04-15 Application granted granted Critical

1987-04-15 Publication of ATE26464T1 publication Critical patent/ATE26464T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/819—Multifunctional antigen or antibody
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
- Y10S530/864—Monoclonal

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Life Sciences & Earth Sciences (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AT82303197T 1981-07-01 1982-06-18 Rekombinante monoklonale antikoerper. ATE26464T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/279,248 US4474893A (en)	1981-07-01	1981-07-01	Recombinant monoclonal antibodies
EP82303197A EP0068763B2 (en)	1981-07-01	1982-06-18	Recombinant monoclonal antibodies

Publications (1)

Publication Number	Publication Date
ATE26464T1 true ATE26464T1 (de)	1987-04-15

Family

ID=23068220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT82303197T ATE26464T1 (de)	1981-07-01	1982-06-18	Rekombinante monoklonale antikoerper.

Country Status (6)

Country	Link
US (1)	US4474893A (2)
EP (1)	EP0068763B2 (2)
JP (3)	JPS5859994A (2)
AT (1)	ATE26464T1 (2)
CA (1)	CA1190873A (2)
DE (1)	DE3276007D1 (2)

Families Citing this family (673)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4401764A (en) *	1980-02-07	1983-08-30	Technicon Instruments Corporation	Immunoassays employing labeled reagent and a conjugate having two binding sites
US4714681A (en) *	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
JP3177776B2 (ja) *	1988-09-27	2001-06-18	武田薬品工業株式会社	ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) *	1981-12-21	1994-03-08	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
US4444878A (en) *	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
CH652145A5 (de) *	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
CA1209907A (en) *	1982-04-12	1986-08-19	Richard M. Bartholomew	Method of affinity purification employing monoclonal antibodies
CA1213229A (en) *	1982-04-12	1986-10-28	Gary S. David	Antibodies having dual specificities, their preparation and uses therefor
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8318575D0 (en) *	1983-07-08	1983-08-10	Cobbold S P	Antibody preparations
CA1231067A (en) *	1983-08-16	1988-01-05	Bioclones (Proprietary) Limited	Monoclonal antibody to peroxidase and hybridoma producing it
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) *	1983-09-01	1992-01-22	Hybritech Incorporated	Antibody compositions of therapeutic agents having an extended serum half-life
US4777245A (en) *	1984-01-06	1988-10-11	Genelabs Incorporated	Non-human primate monoclonal antibodies and methods
US4634666A (en) *	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
JPH0617909B2 (ja) *	1984-04-23	1994-03-09	ボストンバイオメディカルリサーチインスティテュート，インコーポレイテッド	双特異性抗体決定子
US4649106A (en) *	1984-06-01	1987-03-10	Dana-Farber Cancer Institute, Inc.	Distinguishing subsets of human cells
US4722892A (en) *	1984-08-31	1988-02-02	Meares Claude F	Monoclonal antibodies against metal chelates
GB8422238D0 (en) *	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4590071A (en) *	1984-09-25	1986-05-20	Xoma Corporation	Human melanoma specific immunotoxins
US4818679A (en) *	1985-02-19	1989-04-04	The Trustees Of Columbia University In The City Of New York	Method for recovering mutant cells
CH670098B (2) *	1985-05-23	1989-05-12
US4831122A (en) *	1986-01-09	1989-05-16	Regents Of The University Of Minnesota	Radioimmunotoxins
EP0262211A1 (en) *	1986-04-01	1988-04-06	Genelabs, Incorporated	Immortalized cells which produce tissue-specific products
AU613310B2 (en) *	1986-04-01	1991-08-01	Genelabs Incorporated	Immortalized virus-specific tissue cells
US5453269A (en) *	1986-04-14	1995-09-26	The General Hospital Corporation	Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
EP0241907A3 (en) *	1986-04-14	1989-09-13	The General Hospital Corporation	Heterobifunctional antibodies and method of use
JPS62244392A (ja) *	1986-04-15	1987-10-24	Snow Brand Milk Prod Co Ltd	ハイブリド−マを用いて抗体を産生する方法
US4954617A (en) *	1986-07-07	1990-09-04	Trustees Of Dartmouth College	Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US7384735B1 (en)	1986-08-11	2008-06-10	Massachusetts Eye And Ear Infirmary	Retinoblastoma nucleic acids
US5853988A (en) *	1986-08-11	1998-12-29	Massachusetts Eye And Ear Infirmary	Diagnosis of retinoblastoma
US7223842B1 (en)	1986-08-11	2007-05-29	Massachusetts Eye And Ear Infirmary	Detection of proteins whose absence is associated with a neoplasm
FR2604092B1 (fr) *	1986-09-19	1990-04-13	Immunotech Sa	Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US4874693A (en) *	1986-10-10	1989-10-17	Mark Bogart	Method for assessing placental dysfunction
GB8626413D0 (en) *	1986-11-05	1986-12-03	Gilliland L K	Antibodies
GB8626412D0 (en) *	1986-11-05	1986-12-03	Clark M R	Antibodies
US5258498A (en) *	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) *	1987-05-21	2003-07-15	Micromet Ag	Multifunktionelle proteine mit vorbestimmter zielsetzung
US5132405A (en) *	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en) *	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
EP0371056A4 (en) *	1987-08-07	1990-12-19	Xoma Corporation	Methods and compositions for mimicking antigenic determinants
US5086002A (en) *	1987-09-07	1992-02-04	Agen Biomedical, Ltd.	Erythrocyte agglutination assay
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
US6710169B2 (en)	1987-10-02	2004-03-23	Genentech, Inc.	Adheson variants
FR2622444B1 (fr) *	1987-10-30	1990-08-03	Pasteur Institut	Application de dinitro-trinitrophenyle et de ses derives ou d'anticorps anti-nitrophenyles a la modification de l'interaction entre des cellules sensibles d'un hote et un agent pathogene
US4978745A (en) *	1987-11-23	1990-12-18	Centocor, Inc.	Immunoreactive heterochain antibodies
US5750375A (en) *	1988-01-22	1998-05-12	Zymogenetics, Inc.	Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) *	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) *	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
EP0329184A3 (en) *	1988-02-19	1990-05-23	Neorx Corporation	Antimers and antimeric conjugation
US4892824A (en) *	1988-03-15	1990-01-09	Synbiotics Corporation	Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) *	1988-04-04	1996-12-10	General Hospital Corporation	Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) *	1988-04-04	1994-12-13	The General Hospital Corporation	Composition and method for acceleration of clot lysis
EP0338497A3 (en) *	1988-04-22	1990-05-16	Takeda Chemical Industries, Ltd.	Bispecific hybrid monoclonal antibody
GB8813527D0 (en) *	1988-06-08	1988-07-13	Glennie M J	Bispecific antibodies
US5609869A (en) *	1988-08-19	1997-03-11	The General Hospital Corporation	Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5811265A (en) *	1988-08-19	1998-09-22	The General Hospital Corporation	Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
FR2637600B1 (fr) *	1988-10-11	1992-03-06	Pasteur Institut	Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5242824A (en) *	1988-12-22	1993-09-07	Oncogen	Monoclonal antibody to human carcinomas
WO1990006772A1 (en) *	1988-12-22	1990-06-28	Oncogen Limited Partnership	Novel monoclonal antibody to human carcinomas
CA2006408A1 (en) *	1988-12-27	1990-06-27	Susumu Iwasa	Bispecific monoclonal antibody, its production and use
US5134075A (en) *	1989-02-17	1992-07-28	Oncogen Limited Partnership	Monoclonal antibody to novel antigen associated with human tumors
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5639624A (en) *	1989-03-14	1997-06-17	Board Of Regents Of The University Of Nebraska	Monoclonal antibodies specific for metallic cations and method therefor
EP0463110B1 (en) *	1989-03-14	1998-01-07	Board Of Regents Of The University Of Nebraska	Monoclonal antibodies for metallic cations
US5972656A (en) *	1989-03-14	1999-10-26	Bionebraska, Inc.	Mercury binding polypeptides and nucleotides coding therefore
DE3909708A1 (de) *	1989-03-23	1990-09-27	Boehringer Mannheim Gmbh	Verfahren zur herstellung bispezifischer antikoerper
US5316932A (en) *	1989-03-24	1994-05-31	Duke University	Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme
US5171665A (en) *	1989-04-17	1992-12-15	Oncogen	Monoclonal antibody to novel antigen associated with human tumors
US5252711A (en) *	1989-06-01	1993-10-12	The Gillette Company	Monoclonal antibodies useful in deodorizing skin and antibody fragments thereof
IL94872A (en) *	1989-06-30	1995-03-30	Oncogen	Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5980896A (en) *	1989-06-30	1999-11-09	Bristol-Myers Squibb Company	Antibodies reactive with human carcinomas
US6020145A (en) *	1989-06-30	2000-02-01	Bristol-Myers Squibb Company	Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE3924746A1 (de) *	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US6932968B1 (en)	1989-07-26	2005-08-23	Dade Behring Marburg Gmbh	Erythropoietin (EPO) peptides and antibodies directed against these
US5112951A (en) *	1989-07-28	1992-05-12	Hybritech Incorporated	Separation of anti-metal chelate antibodies
JPH05501351A (ja) *	1989-08-16	1993-03-18	カイロン　コーポレイション	プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
US5264341A (en) *	1989-08-30	1993-11-23	Eli Lilly And Company	Selective cloning for high monoclonal antibody secreting hybridomas
US5583003A (en) *	1989-09-25	1996-12-10	Agen Limited	Agglutination assay
GB8921880D0 (en) *	1989-09-28	1989-11-15	Medical Res Council	Improvements in or relating to hybridomas
EP0515571B1 (en) *	1990-02-16	1998-12-02	Boston Biomedical Research Institute	Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (2) *	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
US7041293B1 (en) *	1990-04-03	2006-05-09	Genentech, Inc.	HIV env antibodies
EP0460607A3 (en) *	1990-06-05	1992-04-01	Bristol-Myers Squibb Company	Novel monoclonal antibody to novel antigen associated with human tumors
GB9012995D0 (en) *	1990-06-11	1990-08-01	Celltech Ltd	Multivalent antigen-binding proteins
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6248332B1 (en)	1990-10-05	2001-06-19	Medarex, Inc.	Targeted immunostimulation with bispecific reagents
EP0557300B1 (en) *	1990-10-29	1997-11-19	Chiron Corporation	Bispecific antibodies, method of production, and uses thereof
JPH06506115A (ja) *	1991-03-14	1994-07-14	ジェネンテク，インコーポレイテッド	新規ベータインテグリンサブユニット
WO1992020746A1 (en) *	1991-05-14	1992-11-26	Hybritech, Incorporated	Polymeric compositions having bound antibodies
SE469451B (sv) *	1991-06-28	1993-07-05	Anders Larsson	Karakterisering eller bestaemning av maengden mammalieceller medelst antikroppar
JP2555804B2 (ja) *	1991-07-11	1996-11-20	日東紡績株式会社	前立腺由来酸性ホスファターゼに対するモノクローナル抗体、それを用いた測定法及び測定用キット
EP0611306B1 (en) *	1991-11-08	1998-07-08	Somatogen, Inc.	Hemoglobins as drug delivery agents
US5635177A (en)	1992-01-22	1997-06-03	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
JPH05244987A (ja) *	1992-02-28	1993-09-24	Unitika Ltd	抗硫酸化チロシン抗体，その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ
US5518887A (en) *	1992-03-30	1996-05-21	Abbott Laboratories	Immunoassays empolying generic anti-hapten antibodies and materials for use therein
US6096289A (en) *	1992-05-06	2000-08-01	Immunomedics, Inc.	Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH07506727A (ja) *	1992-05-22	1995-07-27	アジェン・リミテッド	凝集アッセイ用試薬
US6329507B1 (en) *	1992-08-21	2001-12-11	The Dow Chemical Company	Dimer and multimer forms of single chain polypeptides
US6063621A (en) *	1992-10-27	2000-05-16	Queen's University At Kingston	Antibodies to a multidrug resistance protein
US5882875A (en) *	1992-10-27	1999-03-16	Queen's University At Kingston	Methods for identifying multidrug resistant tumor cells
WO1994013806A1 (en) *	1992-12-11	1994-06-23	The Dow Chemical Company	Multivalent single chain antibodies
JP2553445B2 (ja) *	1992-12-17	1996-11-13	同仁医薬化工株式会社	抗体の安定化方法
WO1994014475A1 (en) *	1992-12-21	1994-07-07	Tanox Biosystems, Inc.	ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0608117A3 (en) *	1993-01-20	1996-01-17	Ono Pharmaceutical Co	Antibodies for mevalonic acid and methods for determination of mevalonic acid.
US5705614A (en) *	1993-04-09	1998-01-06	Chiron Corporation	Methods of producing antigen forks
US5466784A (en) *	1993-06-23	1995-11-14	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to salinomycin and method for detecting the same
EP0650735A3 (en) *	1993-07-09	1999-04-14	Akzo Nobel N.V.	Kit and method for pretargeting
US5491071A (en) *	1993-08-03	1996-02-13	Abbott Laboratories	Reagents and methods for the detection and quantification of testosterone in fluid samples
WO1995008637A1 (en) *	1993-09-21	1995-03-30	Washington State University Research Foundation	Immunoassay comprising ligand-conjugated, ion channel receptor immobilized in lipid film
US5476939A (en) *	1993-12-30	1995-12-19	Abbott Laboratories	Certain pyridyl and isoquinolyl carbinolamine derivatives
US5877016A (en)	1994-03-18	1999-03-02	Genentech, Inc.	Human trk receptors and neurotrophic factor inhibitors
US7258983B2 (en)	1994-04-25	2007-08-21	Genentech, Inc.	Cardiotrophin-1 compositions and methods for the treatment of tumor
US5545527A (en) *	1994-07-08	1996-08-13	Visible Genetics Inc.	Method for testing for mutations in DNA from a patient sample
US5728821A (en) *	1994-08-04	1998-03-17	Bristol-Myers Squibb Company	Mutant BR96 antibodies reactive with human carcinomas
US5792456A (en) *	1994-08-04	1998-08-11	Bristol-Myers Squibb Company	Mutant BR96 antibodies reactive with human carcinomas
US5972703A (en) *	1994-08-12	1999-10-26	The Regents Of The University Of Michigan	Bone precursor cells: compositions and methods
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7597886B2 (en) *	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US20030086922A1 (en) *	1994-12-02	2003-05-08	David B. Ring	Method of promoting an immune response with a bispecific antibody
EP0795014B1 (en) *	1994-12-02	2008-01-16	Schering Corporation	Costimulatory T cell surface antigen SLAM
DE69530107T2 (de) *	1994-12-28	2003-10-16	University Of Kentucky, Lexington	Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US20040258688A1 (en) *	1995-01-31	2004-12-23	Daniel Hawiger	Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) *	1995-01-31	2002-12-12	Daniel Hawiger	Enhanced antigen delivery and modulation of the immune response therefrom
JPH08311100A (ja) *	1995-03-13	1996-11-26	Terumo Corp	ヒト肺腺癌に関するモノクローナル抗体および抗原、及びそれを用いた免疫測定方法
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US5837263A (en) *	1995-05-19	1998-11-17	The Regents Of The University Of California	Leptospira membrane proteins
US6111079A (en) *	1995-06-05	2000-08-29	Bionebraska, Inc.	Lead binding polypeptides and nucleotides coding therefore
US5686071A (en) *	1995-06-06	1997-11-11	Per Immune Holdings, Inc.	Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease
US6117985A (en)	1995-06-16	2000-09-12	Stemcell Technologies Inc.	Antibody compositions for preparing enriched cell preparations
US6306575B1 (en) *	1995-06-16	2001-10-23	Stemcell Technologies, Inc.	Methods for preparing enriched human hematopoietic cell preparations
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
US6350571B1 (en)	1996-02-01	2002-02-26	Vinata B. Lokeshwar	Methods for detection and evaluation of bladder cancer
DE19605105A1 (de) *	1996-02-12	1997-08-14	Gsf Forschungszentrum Umwelt	Neue Sonde zur Früherkennung von epithelialen Dysplasien des mehrschichtigen Plattenepithels sowie zur Tumordiagnostik und Tumortherapie von Plattenepithelkarzinomen
EP0888125B1 (en) *	1996-03-20	2004-05-26	Immunomedics, Inc.	GLYCOSYLATED IgG ANTIBODIES
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en) *	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US7011812B1 (en)	1996-05-03	2006-03-14	Immunomedics, Inc.	Targeted combination immunotherapy of cancer and infectious diseases
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5858683A (en)	1996-08-30	1999-01-12	Matritech, Inc.	Methods and compositions for the detection of cervical cancer
ATE218143T1 (de)	1996-09-03	2002-06-15	Gsf Forschungszentrum Umwelt	Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
EP0937146A2 (en) *	1996-09-20	1999-08-25	The General Hospital Corporation	Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US6348581B1 (en) *	1996-10-31	2002-02-19	The Dow Chemical Company	High affinity humanized anti-TAG-72 monoclonalantibodies
US6541212B2 (en) *	1997-03-10	2003-04-01	The Regents Of The University Of California	Methods for detecting prostate stem cell antigen protein
US6261791B1 (en) *	1997-03-10	2001-07-17	The Regents Of The University Of California	Method for diagnosing cancer using specific PSCA antibodies
EP0970227B1 (en) *	1997-03-20	2008-01-09	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US7033774B2 (en) *	1997-04-21	2006-04-25	Glycozyme, Inc.	Determination of recombinant glycosylated proteins and peptides in biological fluids
SE9702120D0 (sv) *	1997-06-04	1997-06-04	Karolinska Innovations Ab	New selection marker
US6309874B1 (en)	1997-06-04	2001-10-30	Karolinska Innovations Ab	Selection marker
US20020098190A1 (en) *	1997-06-13	2002-07-25	Malaya Chatterjee	Compositions and methods for treating tumors bearing HMFG and CEA antigens
US6207805B1 (en) *	1997-07-18	2001-03-27	University Of Iowa Research Foundation	Prostate cell surface antigen-specific antibodies
ES2322975T3 (es)	1998-01-15	2009-07-02	Center For Molecular Medicine And Immunology	Componente direccionador biespecifico que comprende un anticuerpo contra el antigeno carcinoembrionario (cea) y la region de union a ligando de la subunidad alfa del receptor de il-13.
AU3072799A (en)	1998-03-19	1999-10-11	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
WO1999066027A1 (en) *	1998-06-15	1999-12-23	The Research Foundation Of State University Of New York	Monoclonal antibodies that recognize antigens associated with tumor metastasis
GB9815909D0 (en)	1998-07-21	1998-09-16	Btg Int Ltd	Antibody preparation
US6140083A (en) *	1998-07-23	2000-10-31	The Regents Of The University Of California	Leptospiral outer membrane protein, LipL46
GB9819411D0 (en) *	1998-09-04	1998-10-28	Ks Biomedix Ltd	Antibodies
EP2357192A1 (en)	1999-02-26	2011-08-17	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
EP1210428B1 (en)	1999-08-23	2015-03-18	Dana-Farber Cancer Institute, Inc.	Pd-1, a receptor for b7-4, and uses therefor
IL148079A0 (en)	1999-08-24	2002-09-12	Medarex Inc	Human ctla-4 antibodies and compositions containing the same
US7897140B2 (en)	1999-12-23	2011-03-01	Health Research, Inc.	Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
CA2400206A1 (en) *	2000-02-17	2001-08-23	Cv Therapeutics, Inc.	Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
EP2206720A1 (en)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Albumin fusion proteins
US7094882B2 (en) *	2000-04-21	2006-08-22	Yeda Research And Development Co. Ltd.	Growth factor which acts through erb b-4 rtk
EP1284752A4 (en) *	2000-04-26	2004-08-18	Elusys Therapeutics Inc	BISPECIFIC MOLECULES AND USES THEREOF
ATE553131T1 (de) *	2000-05-08	2012-04-15	Celldex Res Corp	Humane monoklonale antikörper gegen dendritische zellen
US7560534B2 (en)	2000-05-08	2009-07-14	Celldex Research Corporation	Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7700359B2 (en) *	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
US20060141455A1 (en)	2002-01-08	2006-06-29	Rhonda Hansen	Gene products differentially expressed in cancerous breast cells and their methods of use
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
CA2413160A1 (en)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en)	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
WO2001097855A2 (en) *	2000-06-20	2001-12-27	Immunomedics, Inc.	Targeted combination immunotherapy of cancer and infectious diseases
EP2412384A1 (en)	2000-11-28	2012-02-01	MedImmune, LLC	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040018194A1 (en)	2000-11-28	2004-01-29	Francisco Joseph A.	Recombinant anti-CD30 antibodies and uses thereof
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
US20020187100A1 (en) *	2000-12-21	2002-12-12	David Rizzieri	Anti-tenascin monoclonal antibody therapy for lymphoma
EP1683865A3 (en)	2001-02-02	2006-10-25	Eli Lilly & Company	Mammalian proteins and in particular CD200
JP2005503116A (ja)	2001-02-09	2005-02-03	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
WO2002098370A2 (en) *	2001-03-02	2002-12-12	Medimmune, Inc.	Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2002303181A1 (en) *	2001-03-30	2002-10-15	University Of Massachusetts	Morpholino imaging and therapy
EP2388590A1 (en)	2001-04-02	2011-11-23	Dana Farber Cancer Institute	PD-1, a receptor for B7-4, and uses thereof
CA2444632A1 (en)	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
WO2002085405A2 (en)	2001-04-24	2002-10-31	Merck Patent Gmbh	COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
EP1390497A2 (en) *	2001-05-25	2004-02-25	Genset	Human cdnas and proteins and uses thereof
US20070015144A9 (en) *	2001-05-25	2007-01-18	Genset, S.A.	Human cDNAs and proteins and uses thereof
PH12012502440A1 (en)	2001-06-26	2013-06-17	Amgen Inc	Antibodies to opgl
EP1414517A4 (en) *	2001-06-26	2008-02-06	Photomed Technologies Inc	Multiple wavelength illuminator
JP2005501536A (ja) *	2001-07-18	2005-01-20	バイオノミックスリミテッド	イオンチャネルにおける変異
AU2003904154A0 (en) *	2003-08-07	2003-08-21	Bionomics Limited	Mutations in ion channels
US6867189B2 (en) *	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20030035802A1 (en) *	2001-08-14	2003-02-20	Dewan Zeng	Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7052860B2 (en)	2001-11-28	2006-05-30	University Of Florida Research Foundation	Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
EP2261250B1 (en)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	GCSF-Albumin fusion proteins
US20050069549A1 (en)	2002-01-14	2005-03-31	William Herman	Targeted ligands
JP2005523688A (ja) *	2002-01-18	2005-08-11	ブリストル−マイヤーズ　スクイブ　カンパニー	タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
WO2003104428A2 (en) *	2002-01-21	2003-12-18	Vaccinex, Inc.	Gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU2003217930A1 (en) *	2002-03-04	2003-09-22	Medimmune, Llc	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
WO2003086289A2 (en)	2002-04-05	2003-10-23	Amgen Inc.	Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7371383B2 (en) *	2002-04-12	2008-05-13	Medimmune, Inc.	Recombinant anti-interleukin-9 antibodies
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1517684B1 (en)	2002-06-27	2009-07-22	Health Research, Inc.	Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en)	2002-07-02	2004-01-15	Health Research, Inc.	Efficient synthesis of pyropheophorbide a and its derivatives
EP1534335B9 (en)	2002-08-14	2016-01-13	Macrogenics, Inc.	Fcgammariib-specific antibodies and methods of use thereof
SI2301965T1 (sl)	2002-10-16	2015-07-31	Purdue Pharma L.P.	Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
CN101928344B (zh)	2002-10-17	2014-08-13	根马布股份公司	抗cd20的人单克隆抗体
AU2003299971A1 (en) *	2002-12-30	2004-07-29	Amgen Inc.	Combination therapy with co-stimulatory factors
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
EP1585815A4 (en) *	2003-01-21	2006-02-22	Bristol Myers Squibb Co	A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
US7563869B2 (en)	2003-01-23	2009-07-21	Ono Pharmaceutical Co., Ltd.	Substance specific to human PD-1
US9259459B2 (en) *	2003-01-31	2016-02-16	Celldex Therapeutics Inc.	Antibody vaccine conjugates and uses therefor
CA2514979A1 (en) *	2003-01-31	2004-09-02	Celldex Therapeutics, Inc.	Antibody vaccine conjugates and uses therefor
AU2004213053C1 (en)	2003-02-20	2009-07-16	Seagen Inc.	Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2003901425A0 (en) *	2003-03-27	2003-04-10	Bionomics Limited	A diagnostic method for epilepsy
CA2520389A1 (en) *	2003-03-28	2004-10-14	Elusys Therapeutics, Inc.	Method and compositions for conversion of antibody activity
JP4764818B2 (ja)	2003-04-11	2011-09-07	メディミューン，エルエルシー	組換えｉｌ−９抗体およびその使用
US8613922B2 (en)	2003-04-24	2013-12-24	The University Of North Carolina At Chapel Hill	Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
JP2008500011A (ja) *	2003-05-09	2008-01-10	ユニバーシティーオブマサチューセッツ	赤血球上に異種補体受容体タイプ１（ｃｒ１）分子を発現する非ヒト動物及びその使用
US7057100B2 (en) *	2003-06-26	2006-06-06	The J.C. Robinson Seed Co.	Inbred corn line W23129
WO2005009363A2 (en) *	2003-07-21	2005-02-03	Medimmune, Inc.	Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
EP1648935A2 (en)	2003-07-25	2006-04-26	Amgen Inc.	Antagonists and agonists of ldcam and methods of use
US7416852B2 (en)	2003-08-15	2008-08-26	University Of Florida Research Foundation	Identification of Porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
WO2005035754A1 (ja)	2003-10-14	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en) *	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
CA2548180C (en) *	2003-12-04	2014-02-04	Vaccinex, Inc.	Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2005058961A2 (en) *	2003-12-12	2005-06-30	Amgen Inc.	Antibodies specific for human galanin, and uses thereof
SG10201404273QA (en)	2003-12-23	2014-10-30	Genentech Inc	Novel anti-il 13 antibodies and uses thereof
ES2567634T3 (es)	2004-02-09	2016-04-25	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina
US7311906B2 (en) *	2004-04-30	2007-12-25	Brigham Young University	Anti-viral activity of an anti-thymidine kinase monoclonal antibody
US20050260131A1 (en) *	2004-05-20	2005-11-24	General Electric Company	Pharmaceuticals for enhanced delivery to disease targets
US20100266495A1 (en) *	2004-05-21	2010-10-21	Brigham Young University	Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
US7837998B2 (en) *	2004-05-21	2010-11-23	Nathaniel Lallatin	Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
US8551486B2 (en) *	2004-05-21	2013-10-08	Savoy Pharmaceuticals, Inc.	Monoclonal antibodies to human thymidine kinase to treat cancer
US7973134B2 (en) *	2004-07-07	2011-07-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
CA2576193A1 (en)	2004-08-03	2006-02-16	Biogen Idec Ma Inc.	Taj in neuronal function
WO2006034292A2 (en)	2004-09-21	2006-03-30	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7306785B2 (en) *	2004-09-23	2007-12-11	General Electric Company	Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
US7935790B2 (en) *	2004-10-04	2011-05-03	Cell Singaling Technology, Inc.	Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US20060121042A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005302312A1 (en) *	2004-10-29	2006-05-11	Elusys Therapeutics, Inc.	Use of CR1-binding molecules in clearance and induction of immune responses
US20060115862A1 (en) *	2004-11-17	2006-06-01	Duke University	Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
US20060127311A1 (en) *	2004-11-17	2006-06-15	Duke University	Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
US7807789B2 (en) *	2004-12-21	2010-10-05	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006073921A2 (en) *	2004-12-30	2006-07-13	The Rockefeller University	Compositions and methods for enhanced dendritic cell maturation and function
KR101335798B1 (ko)	2005-02-15	2013-12-02	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
EP2567976B1 (en)	2005-03-23	2017-07-19	Genmab A/S	Antibodies against CD38 for treatment of multiple myeloma
AU2006230099B2 (en)	2005-03-25	2012-04-19	Gitr, Inc.	GITR binding molecules and uses therefor
EP3050963B1 (en)	2005-03-31	2019-09-18	Chugai Seiyaku Kabushiki Kaisha	Process for production of polypeptide by regulation of assembly
WO2006107924A2 (en)	2005-04-04	2006-10-12	Idexx Laboratories, Inc.	Ehrlichia canis diva (differentiate infected from vaccinated animals)
CA2603940A1 (en) *	2005-04-08	2006-10-19	Nancy Ulbrandt	Antibodies against mammalian metapneumovirus
CA2603264C (en) *	2005-04-08	2017-03-21	Chugai Seiyaku Kabushiki Kaisha	Antibody substituting for function of blood coagulation factor viii
US20090099340A1 (en) *	2007-10-12	2009-04-16	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CN101203241B (zh)	2005-04-19	2012-02-22	西雅图基因公司	人源化抗-cd70结合物和其应用
US20060257317A1 (en) *	2005-05-04	2006-11-16	Duke University	Combination therapy in the treatment of cancer
CA2607281C (en)	2005-05-05	2023-10-03	Duke University	Anti-cd19 antibody therapy for autoimmune disease
CN102321174B (zh)	2005-05-06	2013-10-16	津莫吉尼蒂克斯公司	Il-31单克隆抗体及使用方法
US20100088778A1 (en) *	2005-06-16	2010-04-08	John Charles Mulley	Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
ES2547463T3 (es)	2005-06-17	2015-10-06	Merck Sharp & Dohme Corp.	Moléculas de unión a ILT3 y usos de las mismas
DK1899378T3 (da)	2005-06-21	2010-02-01	Xoma Technology Ltd	IL-1 beta-bindende antistoffer og fragmenter deraf
EP1893647A2 (en)	2005-06-23	2008-03-05	MedImmune, Inc.	Antibody formulations having optimized aggregation and fragmentation profiles
SI1904104T1 (sl)	2005-07-08	2013-12-31	Biogen Idec Ma Inc.	Protitelesa SP35 in njihova uporaba
US7482124B2 (en) *	2005-07-08	2009-01-27	Bristol-Myers Squibb Company	Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
CA2617594C (en)	2005-08-03	2016-08-02	Grains Research & Development Corporation	Polysaccharide synthases
HUE029465T2 (en)	2005-08-10	2017-02-28	Macrogenics Inc	Identification and engineering of antibodies with variant Fc regions and methods of using same
US20070202512A1 (en) *	2005-08-19	2007-08-30	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
EP1934867A2 (en) *	2005-08-31	2008-06-25	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) *	2005-08-31	2010-06-17	Cell Signaling Technolgy, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1929003A4 (en)	2005-08-31	2009-04-29	Cell Signaling Technology Inc	REAGENTS FOR DETECTION OF PROTEIN PHOSPORYLATION IN CARCINOMA SIGNALING PATHWAYS
WO2007026972A2 (en) *	2005-09-01	2007-03-08	Canon Kabushiki Kaisha	Binding protein molecule
EP1762575A1 (en) *	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
US7422899B2 (en) *	2005-10-05	2008-09-09	Biogen Idec Ma Inc.	Antibodies to the human prolactin receptor
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
EP3299027A1 (en)	2005-11-04	2018-03-28	Genentech, Inc.	Use of complement pathway inhibitors to treat ocular diseases
BRPI0618338A2 (pt)	2005-11-07	2011-08-23	Scripps Resarch Inst	uso de inibidor de sinalização de fator tecidual, método para identificar um agente que inibe a sinalização de tf/viia, composições farmacêuticas e kit
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007064911A1 (en) *	2005-12-02	2007-06-07	Biogen Idec Inc.	Anti-mouse cd20 antibodies and uses thereof
DOP2006000277A (es)	2005-12-12	2007-08-31	Bayer Pharmaceuticals Corp	Anticuerpos anti mn y métodos para su utilización
AU2007207465B2 (en)	2006-01-18	2012-12-06	Merck Patent Gmbh	Specific therapy using integrin ligands for treating cancer
SI2671954T1 (sl)	2006-01-20	2018-11-30	Cell Signaling Technology, Inc.	Translokacija in mutantna ROS kinaza v človeškem ne-drobnoceličnem karcinomu pljuč
US20120208824A1 (en)	2006-01-20	2012-08-16	Cell Signaling Technology, Inc.	ROS Kinase in Lung Cancer
WO2009051846A2 (en)	2007-10-18	2009-04-23	Cell Signaling Technology, Inc.	Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2650306A1 (en)	2006-03-06	2013-10-16	Aeres Biomedical Limited	Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9670269B2 (en)	2006-03-31	2017-06-06	Chugai Seiyaku Kabushiki Kaisha	Methods of modifying antibodies for purification of bispecific antibodies
ES2892925T3 (es)	2006-03-31	2022-02-07	Chugai Pharmaceutical Co Ltd	Métodos para controlar la farmacocinética en sangre de anticuerpos
AU2007235496B2 (en)	2006-03-31	2013-11-21	E. R. Squibb & Sons, L.L.C.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2450437B1 (en)	2006-04-14	2017-05-17	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
WO2007127335A2 (en) *	2006-04-27	2007-11-08	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SG10201504662WA (en)	2006-06-14	2015-07-30	Macrogenics Inc	Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US7777008B2 (en)	2006-06-19	2010-08-17	Tolerx, Inc.	ILT3 binding molecules and uses therefor
CA2656918A1 (en) *	2006-06-22	2007-12-27	Vaccinex, Inc.	Anti-c35 antibodies for treating cancer
HUE030269T2 (en)	2006-06-26	2017-04-28	Macrogenics Inc	FC RIIB-specific antibodies and methods for their use
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
CA2659012A1 (en) *	2006-07-26	2008-01-31	Diamedica Inc.	Methods of diagnosis and treatment for metabolic disorders
US7939636B2 (en) *	2006-08-11	2011-05-10	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) *	2006-08-31	2009-10-15	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
DK2594586T3 (en)	2006-09-01	2014-11-17	Zymogenetics Inc	Monoclonal il-31 antibodies and methods of use thereof
EP2061904A2 (en)	2006-09-06	2009-05-27	Ortho-McNeil Pharmaceutical, Inc.	Biomarkers for assessing response to c-met treatment
EP3569245A1 (en)	2006-09-26	2019-11-20	Genmab A/S	Combination treatment of cd38-expressing tumors
AU2007313300A1 (en)	2006-10-16	2008-04-24	Medimmune, Llc.	Molecules with reduced half-lives, compositions and uses thereof
WO2008070593A2 (en)	2006-12-01	2008-06-12	Seattle Genetics, Inc.	Variant target binding agents and uses thereof
JP5386364B2 (ja)	2006-12-18	2014-01-15	ジェネンテック，インコーポレイテッド	抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
CA2673592C (en)	2006-12-20	2014-03-25	Xoma Technology Ltd.	Methods for the treatment of il-1.beta. related diseases
CN101636168B (zh)	2007-01-09	2013-05-29	比奥根艾迪克Ma公司	Sp35抗体及其用途
CN101588812A (zh)	2007-01-18	2009-11-25	默克专利有限公司	使用整联蛋白配体治疗癌的特异疗法和药物
EP1970384A1 (en)	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP1975184A3 (en) *	2007-03-26	2008-11-26	Cell Signaling Technology, Inc.	Serine or threonine phosphorylation sites
WO2008118324A2 (en)	2007-03-26	2008-10-02	Macrogenics, Inc.	Composition and method of treating cancer with an anti-uroplakin ib antibody
US20080238709A1 (en) *	2007-03-28	2008-10-02	Faramarz Vaziri	One-way communication apparatus with dynamic key generation
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
US7977462B2 (en)	2007-04-19	2011-07-12	Cell Signaling Technology, Inc.	Tyrosine phosphorylation sites
EP2068925A4 (en)	2007-05-07	2011-08-31	Medimmune Llc	ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
HUE036885T2 (hu)	2007-05-14	2018-08-28	Astrazeneca Ab	Eljárás a bazofil-szint csökkentésére
EP1997832A1 (en)	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
CL2008001887A1 (es)	2007-06-29	2008-10-03	Amgen Inc	Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
ES2776406T3 (es)	2007-07-12	2020-07-30	Gitr Inc	Terapias de combinación que emplean moléculas de enlazamiento a GITR
US20090028857A1 (en)	2007-07-23	2009-01-29	Cell Genesys, Inc.	Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US20090087860A1 (en) *	2007-08-24	2009-04-02	Todd John A	Highly sensitive system and methods for analysis of prostate specific antigen (psa)
ES2536772T3 (es)	2007-09-21	2015-05-28	The Regents Of The University Of California	El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
KR101621038B1 (ko)	2007-10-31	2016-05-16	아이덱스 래보러토리즈, 인코포레이티드	에를리히아 카니스 ｄｉｖａ（감염된 동물을 백신접종된 동물과 구별）
NZ599777A (en) *	2007-11-07	2013-09-27	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US9308257B2 (en) *	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
US10365224B2 (en)	2007-12-06	2019-07-30	Genalyte, Inc.	Label-free optical sensors
US8637029B2 (en)	2007-12-20	2014-01-28	Xoma Technology Ltd.	Methods for the treatment of gout
NZ586544A (en) *	2007-12-26	2012-07-27	Vaccinex Inc	Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
AU2009207645B2 (en) *	2008-01-25	2014-11-13	Aarhus Universitet	Selective exosite inhibition of PAPP-A activity against IGFBP-4
CA2713462C (en)	2008-01-29	2020-04-14	Fred Hutchinson Cancer Research Center	Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
US20090220991A1 (en) *	2008-02-29	2009-09-03	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP2260102A1 (en)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
US8163551B2 (en)	2008-05-02	2012-04-24	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2599793A1 (en)	2008-05-29	2013-06-05	Nuclea Biotechnologies, Inc.	Anti-phospho-akt antibodies
US8460657B2 (en)	2008-06-25	2013-06-11	H. Lundbeck A/S	Modulation of the TrpV: Vps10p receptor system for the treatment of pain
WO2009158040A2 (en) *	2008-06-26	2009-12-30	University Of South Florida	Cancer platinum resistance detection and sensitization method
EP2307456B1 (en)	2008-06-27	2014-10-15	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
DK2982695T3 (da)	2008-07-09	2019-05-13	Biogen Ma Inc	Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
US20120128684A1 (en)	2008-08-25	2012-05-24	Burnham Institute For Medical Research	Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
EP2166021A1 (en)	2008-09-16	2010-03-24	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
RU2581962C2 (ru)	2008-09-19	2016-04-20	Медиммун Ллк	Нацеленные средства связывания, направленные на dll4, и их применение
KR101814408B1 (ko)	2008-09-26	2018-01-04	다나-파버 캔서 인스티튜트 인크.	인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
US9846126B2 (en)	2008-10-27	2017-12-19	Genalyte, Inc.	Biosensors based on optical probing and sensing
BRPI0919879A2 (pt)	2008-10-29	2016-02-16	Wyeth Llc	métodos para purificação de moléculas de ligação a antígeno de domínio único
EP2362767B1 (en)	2008-10-29	2017-12-06	Ablynx N.V.	Formulations of single domain antigen binding molecules
EP2356251A1 (en)	2008-11-07	2011-08-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Teneurin and cancer
JP5933975B2 (ja)	2008-11-12	2016-06-15	メディミューン，エルエルシー	抗体製剤
EP3165537A1 (en)	2008-12-19	2017-05-10	H. Lundbeck A/S	Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
WO2010072740A2 (en)	2008-12-23	2010-07-01	Astrazeneca Ab	TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
JP2012514458A (ja)	2008-12-31	2012-06-28	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗リンホトキシン抗体
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AU2010213578B2 (en)	2009-02-12	2015-01-29	Cell Signaling Technology, Inc.	Mutant ROS expression in human cancer
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
CN103382222B (zh)	2009-03-20	2016-12-28	安姆根有限公司	α-4-β-7异二聚体特异性拮抗剂抗体
WO2010112034A2 (en)	2009-04-02	2010-10-07	Aarhus Universitet	Compositions and methods for treatment and diagnosis of synucleinopathies
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
AR076284A1 (es)	2009-04-29	2011-06-01	Bayer Schering Pharma Ag	Inmunoconjugados de antimesotelina y usos de los mismos
ES2647823T3 (es)	2009-05-08	2017-12-26	Vaccinex, Inc.	Anticuerpos anti-CD100 y métodos de uso de los mismos
NZ597339A (en)	2009-05-25	2013-10-25	Merck Patent Gmbh	Continuous administration of cilengitide in cancer treatments
US20120231013A1 (en)	2009-07-31	2012-09-13	Black Roy A	Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
PL2464664T3 (pl) *	2009-08-13	2016-02-29	Crucell Holland Bv	Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
DK2483289T4 (da)	2009-10-02	2025-05-19	Biogen Ma Inc	Fremgangsmåder til forebyggelse og fjernelse af trisulfidbindinger
WO2011044368A1 (en)	2009-10-07	2011-04-14	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011054359A2 (en)	2009-11-06	2011-05-12	University Of Copenhagen	Method for early detection of cancer
WO2011060272A2 (en)	2009-11-13	2011-05-19	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
NZ628923A (en)	2009-11-24	2016-02-26	Medimmune Ltd	Targeted binding agents against b7-h1
WO2011082345A2 (en) *	2009-12-30	2011-07-07	Brigham Young University	Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
TW201129384A (en)	2010-02-10	2011-09-01	Immunogen Inc	CD20 antibodies and uses thereof
WO2011107586A1 (en)	2010-03-05	2011-09-09	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research,	Smoc1, tenascin-c and brain cancers
WO2011112670A2 (en)	2010-03-09	2011-09-15	Board Of Regents, University Of Texas System	Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
EP2371864A1 (en)	2010-03-23	2011-10-05	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
US20130101590A1 (en)	2010-04-09	2013-04-25	Heather A. Arnett	Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011131611A1 (en)	2010-04-19	2011-10-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulating xrn1
AU2011261308C1 (en)	2010-06-03	2016-02-18	Idexx Laboratories, Inc.	Markers for renal disease
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
US8735548B2 (en)	2010-06-30	2014-05-27	Amgen Inc.	Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
PH12012502244A1 (en)	2010-07-09	2016-09-30	Crucell Holland Bv	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
SG10201505217WA (en)	2010-07-09	2015-08-28	Biogen Hemophilia Inc	Chimeric clotting factors
US20120100166A1 (en)	2010-07-15	2012-04-26	Zyngenia, Inc.	Ang-2 Binding Complexes and Uses Thereof
US9220771B2 (en)	2010-07-16	2015-12-29	Merck Patent Gmbh	Peptide for use in the treatment of breast cancer and/or bone metastases
CN108314733A (zh)	2010-07-16	2018-07-24	埃博灵克斯股份有限公司	修饰的单结构域抗原结合分子及其应用
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012022734A2 (en)	2010-08-16	2012-02-23	Medimmune Limited	Anti-icam-1 antibodies and methods of use
US8999343B2 (en)	2010-08-16	2015-04-07	Amgen Inc.	Antibodies that bind myostatin, compositions and methods
AU2011295902B2 (en)	2010-09-02	2014-12-04	Vaccinex, Inc.	Anti-CXCL13 antibodies and methods of using the same
US20130171159A1 (en)	2010-09-10	2013-07-04	Brian Arthur Hemmings	Phosphorylated twist1 and metastasis
AU2011316917B2 (en)	2010-10-22	2016-02-25	Seagen Inc.	Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP3266881B1 (en)	2010-11-05	2019-12-25	Genalyte, Inc.	Optical analyte detection systems and methods of use
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US20140093506A1 (en)	2010-11-15	2014-04-03	Marc Buehler	Anti-fungal-agents
PH12016502073B1 (en)	2010-11-17	2024-04-05	Chugai Pharmaceutical Co Ltd	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CA2825894C (en)	2011-02-02	2021-11-30	Amgen Inc.	Prognosis of cancer using a circulating biomarker
CN103547592A (zh)	2011-03-30	2014-01-29	埃博灵克斯股份有限公司	使用针对TNFα的单结构域抗体治疗免疫病症的方法
KR102023496B1 (ko)	2011-04-21	2019-09-20	시애틀 지네틱스, 인크.	신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
DK2707383T3 (en)	2011-05-13	2018-07-23	Biogen Ma Inc	PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS
WO2012159079A1 (en)	2011-05-18	2012-11-22	The Parkinson's Institute	Assay to determine lrrk2 activity in parkinson's disease
EP2714738B1 (en)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
WO2012168259A1 (en)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
CA2838833A1 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
MX358726B (es)	2011-06-29	2018-09-03	Amgen Inc	Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
US9738707B2 (en)	2011-07-15	2017-08-22	Biogen Ma Inc.	Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
EP2742953B1 (en)	2011-08-11	2021-09-22	ONO Pharmaceutical Co., Ltd.	Therapeutic agent for autoimmune diseases comprising pd-1 agonist
AU2012312520A1 (en)	2011-09-20	2014-05-08	The University Of North Carolina At Chapel Hill	Regulation of sodium channels by PLUNC proteins
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
AU2012332588B2 (en)	2011-11-01	2017-09-07	Bionomics, Inc.	Methods of blocking cancer stem cell growth
EP2773664A1 (en)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49 antibodies
WO2013067054A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Antibodies and methods of treating cancer
CA2854233C (en)	2011-11-04	2020-05-12	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
EP2776838A1 (en)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Early diagnostic of neurodegenerative diseases
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
AU2012351685A1 (en)	2011-12-14	2014-07-03	Seattle Genetics, Inc.	FGFR antibody drug conjugates (ADCs) and the use thereof
US20150017157A1 (en)	2011-12-19	2015-01-15	Xoma (Us) Llc	Methods for treating acne
WO2013102825A1 (en)	2012-01-02	2013-07-11	Novartis Ag	Cdcp1 and breast cancer
MX350378B (es)	2012-01-10	2017-09-05	Biogen Ma Inc	Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
CA2865677C (en)	2012-02-02	2021-08-10	Conicet	Hahb11 provides improved plant yield and tolerance to abiotic stress
EP3575794A1 (en)	2012-02-10	2019-12-04	Seattle Genetics, Inc.	Detection and treatment of cd30+ cancers
NZ629828A (en)	2012-03-02	2017-05-26	Vaccinex Inc	Methods for the treatment of b cell-mediated inflammatory diseases
ES2800426T3 (es)	2012-03-03	2020-12-30	Immungene Inc	Moléculas de fusión anticuerpos-mutante de interferón modificadas
EP2825885B1 (en)	2012-03-12	2021-05-12	The Board of Trustees of the University of Illinois	Optical analyte detection systems with magnetic enhancement
WO2013144240A1 (en)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
DK2838998T3 (en)	2012-04-18	2018-01-15	Cell Signaling Technology Inc	EGFR AND ROS1 IN CANCER
WO2013169693A1 (en)	2012-05-09	2013-11-14	Bristol-Myers Squibb Company	Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2013170054A2 (en)	2012-05-09	2013-11-14	Advanced Animal Diagnostics, Inc.	Autofocus method for imaging a biological sample and cartridge for use therein
WO2013166594A1 (en)	2012-05-10	2013-11-14	Zymeworks Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9512223B2 (en)	2012-05-15	2016-12-06	Morphotek, Inc.	Methods for treatment of gastric cancer
EP2855521A4 (en)	2012-05-24	2016-03-02	Mountgate Group Ltd	COMPOSITIONS AND METHODS RELATED TO PREVENTING AND TREATING TOLL WUTINFECTION
US20150017136A1 (en)	2013-07-15	2015-01-15	Cellectis	Methods for engineering allogeneic and highly active t cell for immunotherapy
US20130315891A1 (en)	2012-05-25	2013-11-28	Matthew Charles	Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
KR102437522B1 (ko)	2012-05-25	2022-08-26	셀렉티스	면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP2854841B1 (en)	2012-06-04	2017-02-22	Diamedica Inc.	Human tissue kallikrein 1 glycosylation isoforms
US10155987B2 (en)	2012-06-12	2018-12-18	Dana-Farber Cancer Institute, Inc.	Methods of predicting resistance to JAK inhibitor therapy
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
EP2869818A1 (en)	2012-07-06	2015-05-13	Novartis AG	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US20140024015A1 (en)	2012-07-18	2014-01-23	Idexx Laboratories, Inc.	Boone Cardiovirus
US20150166630A1 (en)	2012-07-19	2015-06-18	Amgen Inc.	Btnl3 proteins, nucleic acids, and antibodies and uses thereof
ES2771324T3 (es)	2012-08-03	2020-07-06	Dana Farber Cancer Inst Inc	Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
PL3489261T3 (pl)	2012-08-24	2021-08-16	The Regents Of The University Of California	Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
CN104769103B (zh)	2012-09-04	2018-06-08	塞勒克提斯公司	多链嵌合抗原受体和其用途
US9636370B2 (en)	2012-09-28	2017-05-02	The University Of North Carolina At Chapel Hill	AAV vectors targeted to oligodendrocytes
US9309318B2 (en)	2012-10-17	2016-04-12	Amgen, Inc.	Compositions relating to anti-IL-21 receptor antibodies
US10100102B2 (en)	2012-10-29	2018-10-16	The University Of North Carolina At Chapel Hill	Compositions and methods for inhibiting pathogen infection
WO2014122605A1 (en)	2013-02-08	2014-08-14	Friedrich Miescher Institute For Biomedical Research	Novel methods for the targeted introduction of viruses into cells
BR112015021964A2 (pt)	2013-03-08	2017-08-29	Vaccinex Inc	Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
EP2778176A1 (en)	2013-03-12	2014-09-17	Sanofi	Compositions and methods for analyzing histidine phosphorylation
KR20160043927A (ko)	2013-03-14	2016-04-22	파카쉬 길	세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
BR112015023752B1 (pt)	2013-03-15	2023-11-14	Zyngenia, Inc.	Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2014143637A1 (en)	2013-03-15	2014-09-18	The Board Of Trustees Of The University Of Illinois	Methods and compositions for enhancing immunoassays
EP2970483A2 (en)	2013-03-15	2016-01-20	Amgen Inc.	Methods and compositions relating to anti-ccr7 antigen binding proteins
HRP20251426T1 (hr)	2013-05-06	2026-01-02	Scholar Rock, Inc.	Sastavi i postupci za modulaciju faktora rasta
MX2015015638A (es)	2013-05-13	2016-10-28	Cellectis	Metodos para diseñar celulas t altamente activas para inmunoterapia.
US20160115231A1 (en)	2013-05-21	2016-04-28	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Treatment of mast cell related pathologies
WO2014191128A1 (en)	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
EP3004877A4 (en)	2013-06-06	2017-04-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
CA2919477A1 (en)	2013-07-31	2015-02-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP3030902B1 (en)	2013-08-07	2019-09-25	Friedrich Miescher Institute for Biomedical Research	New screening method for the treatment friedreich's ataxia
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
JP6534615B2 (ja)	2013-09-27	2019-06-26	中外製薬株式会社	ポリペプチド異種多量体の製造方法
WO2015050959A1 (en)	2013-10-01	2015-04-09	Yale University	Anti-kit antibodies and methods of use thereof
WO2015066027A2 (en)	2013-10-28	2015-05-07	Dots Devices, Inc.	Allergen detection
US10584147B2 (en)	2013-11-08	2020-03-10	Biovertiv Therapeutics Inc.	Procoagulant fusion compound
EP3076963A4 (en)	2013-12-06	2017-09-13	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd30 antibodies
AU2014365838B2 (en)	2013-12-16	2021-01-14	The University Of North Carolina At Chapel Hill	Depletion of plasmacytoid dendritic cells
WO2015095868A1 (en)	2013-12-20	2015-06-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
PL3086814T3 (pl)	2013-12-23	2020-12-28	Bayer Pharma Aktiengesellschaft	Koniugaty środka wiążącego (ADC) z inhibitorami KSP
CA2935804A1 (en)	2014-01-14	2015-07-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
BR112016017132B1 (pt)	2014-01-28	2024-01-30	Quest Diagnostics Investments Incorporated	Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).
US20160152725A1 (en)	2014-02-25	2016-06-02	Memorial Sloan-Kettering Cancer Center	Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
MX373460B (es)	2014-03-11	2020-04-07	Cellectis	Metodo para generar celulas t compatibles para el trasplante alogenico.
WO2015143335A1 (en)	2014-03-20	2015-09-24	The University Of North Carolina At Chapel Hill	Methods and compositions for chimeric coronavirus spike proteins
CA2944649C (en)	2014-04-04	2022-06-21	Bionomics, Inc.	Humanized antibodies that bind lgr5
RU2689145C2 (ru)	2014-04-16	2019-05-24	Биокон Лтд.	Стабильные белковые препараты, содержащие молярный избыток сорбитола
EP3142700B1 (en)	2014-05-16	2021-03-03	Medimmune, LLC	Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015189816A1 (en)	2014-06-13	2015-12-17	Friedrich Miescher Institute For Biomedical Research	New treatment against influenza virus
US9631024B2 (en)	2014-06-23	2017-04-25	Bionomics, Inc.	Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
WO2015198202A1 (en)	2014-06-23	2015-12-30	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
WO2016001830A1 (en)	2014-07-01	2016-01-07	Friedrich Miescher Institute For Biomedical Research	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
EP3183002B1 (en)	2014-08-21	2021-03-03	Walter Reed Army Institute of Research	Monoclonal antibodies for treatment of microbial infections
AU2015313811A1 (en)	2014-09-08	2017-04-06	Yeda Research And Development Co. Ltd.	Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
TWI701435B (zh)	2014-09-26	2020-08-11	日商中外製藥股份有限公司	測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh)	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
IL313511A (en)	2014-11-12	2024-08-01	Seagen Inc	Compounds acting on glycans and methods of using them
WO2016081811A1 (en)	2014-11-21	2016-05-26	The University Of North Carolina At Chapel Hill	Aav vectors targeted to the central nervous system
US11033637B2 (en)	2014-11-21	2021-06-15	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
CA2968352A1 (en)	2014-12-08	2016-06-16	Dana-Farber Cancer Institute, Inc.	Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
CN107635586B (zh)	2014-12-15	2021-09-24	拜耳医药股份有限公司	Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
WO2016149621A1 (en)	2015-03-18	2016-09-22	The Johns Hopkins University	Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
KR102261618B1 (ko)	2015-03-31	2021-06-04	메디뮨 리미티드	신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
JP7082484B2 (ja)	2015-04-01	2022-06-08	中外製薬株式会社	ポリペプチド異種多量体の製造方法
RU2751512C2 (ru)	2015-06-22	2021-07-14	Байер Фарма Акциенгезельшафт	Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
US11071788B2 (en)	2015-06-23	2021-07-27	Bayer Pharma Aktiengesellschaft	Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
RU2018102358A (ru)	2015-06-23	2019-07-25	Байер Фарма Акциенгезельшафт	Нацеленные конъюгаты ksp ингибиторов
WO2016207094A1 (de)	2015-06-23	2016-12-29	Bayer Pharma Aktiengesellschaft	Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
EP4043556B1 (en)	2015-06-30	2024-02-07	Cellectis	Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
CA2995838A1 (en)	2015-08-19	2017-02-23	Rutgers, The State University Of New Jersey	Novel methods of generating antibodies
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
WO2017072669A1 (en)	2015-10-28	2017-05-04	Friedrich Miescher Institute For Biomedical Research	Tenascin-w and biliary tract cancers
EP3371217B1 (en)	2015-11-08	2025-06-11	F. Hoffmann-La Roche AG	Methods of screening for multispecific antibodies
EP3373969A4 (en)	2015-11-12	2019-08-14	Siamab Therapeutics, Inc.	GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
EP3176183A1 (en)	2015-12-02	2017-06-07	Yeda Research and Development Co. Ltd	Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US20200270363A1 (en)	2015-12-25	2020-08-27	Chugai Seiyaku Kabushiki Kaisha	Antibody having enhanced activity, and method for modifying same
CN108368166B (zh)	2015-12-28	2023-03-28	中外制药株式会社	提高含fc区多肽纯化效率的方法
US10960013B2 (en)	2016-03-04	2021-03-30	East Carolina University	J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
EP3432925A4 (en)	2016-03-22	2019-11-06	Bionomics Limited	ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
AU2017236431A1 (en)	2016-03-24	2018-09-27	Bayer Pharma Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
MA44780A (fr)	2016-04-28	2019-03-06	Chugai Pharmaceutical Co Ltd	Préparation contenant un anticorps
WO2017216028A1 (en)	2016-06-15	2017-12-21	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018021301A1 (ja)	2016-07-26	2018-02-01	静岡県	抗ｂ７－ｈ４抗体
KR102591955B1 (ko)	2016-07-29	2023-10-19	추가이 세이야쿠 가부시키가이샤	증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
KR20190077306A (ko)	2016-08-05	2019-07-03	메디뮨 엘엘씨	항-o2 항체 및 이의 용도
US10919904B2 (en)	2016-08-17	2021-02-16	North Carolina State University	Northern-southern route to synthesis of bacteriochlorins
RU2766233C2 (ru)	2016-09-06	2022-02-10	Чугаи Сейяку Кабусики Кайся	Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
KR20190053909A (ko)	2016-09-16	2019-05-20	바이오노믹스 리미티드	항체와 체크포인트 면역 억제제의 병용 요법
WO2018053508A1 (en)	2016-09-19	2018-03-22	The University Of North Carolina At Chapel Hill	Methods and compositions for inducing an immune response
US11117956B2 (en)	2016-10-19	2021-09-14	Medimmune, Llc	Anti-O1 antibodies and uses thereof
EP3541847A4 (en)	2016-11-17	2020-07-08	Seattle Genetics, Inc.	COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
WO2018102252A1 (en)	2016-11-30	2018-06-07	North Carolina State University	Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
JP7106538B2 (ja)	2016-12-07	2022-07-26	アジェナスインコーポレイテッド	抗体およびその使用方法
WO2018112033A1 (en)	2016-12-13	2018-06-21	President And Fellows Of Harvard College	Methods and compositions for targeting tumor-infiltrating tregs
JP7030811B2 (ja)	2016-12-21	2022-03-07	バイエル・ファルマ・アクティエンゲゼルシャフト	Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
JP7066714B2 (ja)	2016-12-21	2022-05-13	バイエル・ファルマ・アクティエンゲゼルシャフト	酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CA3047491A1 (en)	2016-12-21	2018-06-28	Bayer Aktiengesellschaft	Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2018129029A1 (en)	2017-01-04	2018-07-12	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
KR102653141B1 (ko)	2017-03-03	2024-04-01	씨젠 인크.	글리칸-상호작용 화합물 및 사용 방법
CN110446501A (zh)	2017-03-09	2019-11-12	代阿麦迪卡股份有限公司	组织激肽释放酶1的剂型
CN110461358A (zh)	2017-03-31	2019-11-15	公立大学法人奈良县立医科大学	可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
KR102637960B1 (ko)	2017-04-22	2024-02-21	이뮤노믹 쎄라퓨틱스, 인크.	개선된 lamp 구축물
US12358962B2 (en)	2017-05-02	2025-07-15	Immunomic Therapeutics, Inc.	Lamp constructs comprising cancer antigens
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
US11655307B2 (en)	2017-05-30	2023-05-23	The Board Of Regents Of The University Of Oklahoma	Anti-doublecortin-like kinase 1 antibodies and methods of use
JP7009517B2 (ja)	2017-06-21	2022-01-25	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
US12485102B2 (en)	2017-08-02	2025-12-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for treating cancer
SG11202000198QA (en)	2017-08-04	2020-02-27	Genmab As	Binding agents binding to pd-l1 and cd137 and use thereof
WO2019035001A1 (en)	2017-08-18	2019-02-21	Friedrich Miescher Institute For Biomedical Research	NEW METHODS FOR TARGETED INTRODUCTION OF VIRUSES IN CELLS AND TISSUES
AU2018324070B2 (en)	2017-09-01	2023-05-18	East Carolina University	Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
AR113142A1 (es)	2017-09-29	2020-01-29	Chugai Pharmaceutical Co Ltd	Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
EP3693013A4 (en)	2017-10-06	2021-06-30	Ono Pharmaceutical Co., Ltd.	BISPECIFIC ANTIBODY
EP3694559A2 (en)	2017-10-11	2020-08-19	Seattle Genetics, Inc.	Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
US11707522B2 (en)	2017-10-13	2023-07-25	Boehringer Ingelheim International Gmbh	Human antibodies to Tn antigen
AU2018361430B2 (en)	2017-11-01	2025-08-14	Chugai Seiyaku Kabushiki Kaisha	Antibody variant and isoform with lowered biological activity
WO2019089870A1 (en)	2017-11-01	2019-05-09	Seattle Genetics, Inc.	Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
EP3706795A4 (en)	2017-11-09	2021-10-13	Pinteon Therapeutics Inc.	METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
AU2019207535B2 (en)	2018-01-15	2021-12-23	Epiaxis Therapeutics Pty Ltd	Agents and methods for predicting response to therapy
JP2021512103A (ja)	2018-01-31	2021-05-13	バイエルアクチェンゲゼルシャフトＢａｙｅｒＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
TWI849895B (zh)	2018-02-09	2024-07-21	日商小野藥品工業股份有限公司	雙特異性抗體
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US10912788B2 (en)	2018-03-08	2021-02-09	Purepharm, Inc.	Methods and compositions for preventing and treating conditions related to alpha-synuclein
EP3765031A4 (en)	2018-03-14	2022-03-23	Memorial Sloan Kettering Cancer Center	ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF
CA3093731A1 (en)	2018-03-23	2019-09-26	Seattle Genetics, Inc.	Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
KR20210007959A (ko)	2018-04-06	2021-01-20	다나-파버 캔서 인스티튜트 인크.	Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도
WO2019217455A1 (en)	2018-05-07	2019-11-14	Genmab A/S	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en)	2018-05-07	2019-11-14	Genmab A/S	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US12398195B2 (en)	2018-05-15	2025-08-26	Immunomic Therapeutics, Inc.	Lamp constructs comprising allergens
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
CN112566923B (zh)	2018-06-12	2024-10-29	北卡罗来纳大学教堂山分校	合成嗜肝性腺相关病毒衣壳及其用途
JP2021527640A (ja)	2018-06-18	2021-10-14	バイエルアクチェンゲゼルシャフトＢａｙｅｒＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、ｃｘｃｒ５に対して向けられるバインダー／活性薬剤複合体
HRP20250618T1 (hr)	2018-07-03	2025-07-18	Gilead Sciences, Inc.	Protutijela koja ciljaju na hiv gp120 i postupci za uporabu
WO2020014306A1 (en)	2018-07-10	2020-01-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
WO2020037215A1 (en)	2018-08-17	2020-02-20	Icahn School Of Medicine At Mount Sinai	Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
EP3841201A1 (en)	2018-08-24	2021-06-30	Yeda Research and Development Co. Ltd	Methods of modulating m2 macrophage polarization and use of same in therapy
US20210347885A1 (en)	2018-09-21	2021-11-11	The University Of North Carolina At Chapel Hill	Synthetic binding agents for limiting permeation through mucus
MX2021003734A (es)	2018-10-01	2021-07-16	Seagen Inc	Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US12227548B2 (en)	2018-11-19	2025-02-18	Dana-Farber Cancer Institute, Inc.	Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
RU2741095C2 (ru) *	2018-12-29	2021-01-22	Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Способ получения клеточных линий, стабильно продуцирующих человеческие моноклональные антитела класса igg
WO2020163225A1 (en)	2019-02-05	2020-08-13	Seattle Genetics, Inc.	Anti-cd228 antibodies and antibody-drug conjugates
EP3931565A4 (en)	2019-02-27	2023-04-12	Epiaxis Therapeutics Pty Ltd	METHODS AND MEANS OF EVALUATING T-CELL FUNCTION AND PREDICTING RESPONSE TO THERAPY
MX2021010565A (es)	2019-03-08	2021-10-13	Genentech Inc	Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
EP3938400B1 (en)	2019-03-11	2025-07-30	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
CN113874392B (zh)	2019-03-28	2025-10-21	丹尼斯科美国公司	工程化抗体
TWI862565B (zh)	2019-04-04	2024-11-21	日商小野藥品工業股份有限公司	雙特異性抗體
EP3952999A4 (en)	2019-04-09	2023-01-25	Abcuro, Inc.	Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2020223121A1 (en)	2019-04-30	2020-11-05	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US20220249707A1 (en)	2019-05-20	2022-08-11	Nirvana Sciences Inc.	Narrow emission dyes, compositions comprising same, and methods for making and using same
EP3959292B1 (en)	2019-05-20	2025-07-02	NIRvana Sciences Inc.	Narrow emission dyes, compositions comprising same, and methods for making and using same
EP3984554A4 (en)	2019-06-11	2023-11-08	ONO Pharmaceutical Co., Ltd.	IMMUNOSUPPRESSANT
WO2021006199A1 (ja)	2019-07-05	2021-01-14	小野薬品工業株式会社	Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021013693A1 (en)	2019-07-23	2021-01-28	Bayer Pharma Aktiengesellschaft	Antibody drug conjugates (adcs) with nampt inhibitors
WO2021020416A1 (ja)	2019-07-30	2021-02-04	小野薬品工業株式会社	二重特異性抗体
EP4011918A4 (en)	2019-08-08	2023-08-23	ONO Pharmaceutical Co., Ltd.	DUAL SPECIFIC PROTEIN
CN114867751B (zh)	2019-08-12	2024-11-29	阿帕特夫研究和发展有限公司	4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
KR20220069964A (ko)	2019-09-25	2022-05-27	씨젠 인크.	조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합
AU2020358859A1 (en)	2019-10-04	2022-05-12	Seagen Inc.	Anti-PD-L1 antibodies and antibody-drug conjugates
EP4045528A1 (en)	2019-10-18	2022-08-24	Immunomic Therapeutics, Inc.	Improved lamp constructs comprising cancer antigens
AU2020379001A1 (en)	2019-11-04	2022-06-09	Paul RUBINSTEIN	Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
MX2022005222A (es)	2019-11-07	2022-06-08	Genmab As	Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
US20230075965A1 (en)	2020-01-24	2023-03-09	Constantine S. Mitsiades	Uses of biomarkers for improving immunotherapy
MX2022009389A (es)	2020-01-31	2022-10-13	Seagen Inc	Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin.
US12209251B2 (en)	2020-05-05	2025-01-28	The University Of North Carolina At Chapel Hill	Modified adeno-associated virus 5 capsids and uses thereof
CA3183602A1 (en)	2020-05-13	2021-11-18	Seagen Inc.	Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
CN115803062B (zh)	2020-06-03	2025-09-09	博泰康医药公司	滋养层细胞表面抗原2(trop-2)抗体
EP4178624A2 (en)	2020-07-07	2023-05-17	Bionecure Therapeutics, Inc.	Maytansinoids as adc payloads and their use for the treatment of cancer
KR20230042518A (ko)	2020-08-04	2023-03-28	씨젠 인크.	항-cd228 항체 및 항체-약물 컨쥬게이트
CA3192526A1 (en)	2020-09-04	2022-03-10	Rutgers, The State University Of New Jersey	Sars-cov-2 vaccines and antibodies
US11225508B1 (en)	2020-09-23	2022-01-18	The University Of North Carolina At Chapel Hill	Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230382978A1 (en)	2020-10-15	2023-11-30	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
EP4243868A1 (en)	2020-11-11	2023-09-20	BioNTech SE	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022108931A2 (en)	2020-11-17	2022-05-27	Seagen Inc.	Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
US20240301086A1 (en)	2020-12-01	2024-09-12	Aptevo Research And Development Llc	Tumor-associated antigens and cd3-binding proteins, related compositions, and methods
WO2022116877A1 (en)	2020-12-02	2022-06-09	Shanghai Henlius Biotech, Inc.	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN117157318A (zh)	2020-12-30	2023-12-01	免疫治疗有限公司	抗hvem抗体
CA3204628A1 (en)	2021-01-13	2022-07-21	John T. POIRIER	Antibody-pyrrolobenzodiazepine derivative conjugate
TW202245844A (zh)	2021-01-13	2022-12-01	紀念斯隆凱特琳癌症中心	抗dll3抗體-藥物結合物
US12365739B2 (en)	2021-03-24	2025-07-22	Wake Forest University Health Sciences	Monoclonal antibodies to angiotensin-(1-12), compositions including the same, and methods of use thereof
AU2022246164A1 (en)	2021-03-26	2023-09-28	The Brigham And Women’S Hospital, Inc.	Anti-klrg1 antibodies
WO2022204529A1 (en)	2021-03-26	2022-09-29	Abcuro, Inc.	Anti-klrg1 antibodies
WO2022212836A1 (en)	2021-04-01	2022-10-06	Pyxis Oncology, Inc.	Gpnmb antibodies and methods of use
CA3220629A1 (en)	2021-05-28	2022-12-01	Tobin J. CAMMETT	Methods for detecting cm-tma biomarkers
WO2022261183A2 (en)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
JP2024522213A (ja)	2021-06-14	2024-06-11	アルジェニクスビーブイ	抗ｉｌ－９抗体及びその使用方法
JP2024527551A (ja)	2021-06-29	2024-07-25	シージェンインコーポレイテッド	非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法
JP2024525758A (ja)	2021-07-13	2024-07-12	ビオンテック・ソシエタス・エウロパエア	がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
MX2024001277A (es)	2021-07-26	2024-02-15	Abcuro Inc	Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).
EP4130028A1 (en)	2021-08-03	2023-02-08	Rhazes Therapeutics Ltd	Engineered tcr complex and methods of using same
EP4380966A2 (en)	2021-08-03	2024-06-12	Genicity Limited	Engineered tcr complex and methods of using same
US11879010B2 (en)	2021-09-30	2024-01-23	The Charlotte Mecklenburg Hospital Authority	Methods and compositions for pretargeted immunotherapy
US20250002600A1 (en)	2021-10-06	2025-01-02	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 in combination therapy
IL312110A (en)	2021-10-29	2024-06-01	Seagen Inc	Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023083439A1 (en)	2021-11-09	2023-05-19	BioNTech SE	Tlr7 agonist and combinations for cancer treatment
WO2023097119A2 (en)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
JP2025501522A (ja)	2021-12-17	2025-01-22	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｏｘ４０抗体及び使用方法
CN118488965A (zh)	2021-12-17	2024-08-13	上海复宏汉霖生物技术股份有限公司	抗ox40抗体、多特异性抗体及其使用方法
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
WO2023192436A1 (en)	2022-03-31	2023-10-05	Alexion Pharmaceuticals, Inc.	Singleplex or multiplexed assay for complement markers in fresh biological samples
US20250352639A1 (en)	2022-04-10	2025-11-20	Immunomic Therapeutics, Inc.	Bicistronic LAMP Constructs Comprising Immune Response Enhancing Genes and Methods of Use Thereof
CN119546329A (zh)	2022-04-11	2025-02-28	瑞泽恩制药公司	用于通用肿瘤细胞杀伤的组合物和方法
WO2023213960A1 (en)	2022-05-06	2023-11-09	Genmab A/S	Methods of treating cancer with anti-tissue factor antibody-drug conjugates
US11932693B2 (en)	2022-05-12	2024-03-19	BioNTech SE	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2024043227A1 (ja)	2022-08-23	2024-02-29	小野薬品工業株式会社	二重特異性抗体
CN120035450A (zh)	2022-09-06	2025-05-23	阿雷克森制药公司	造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
WO2024059183A1 (en)	2022-09-14	2024-03-21	President And Fellows Of Harvard College	Methods and compositions for modulation of piezo1 in the treatment of cancer
CN120435319A (zh)	2022-11-03	2025-08-05	思进公司	抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
WO2024105205A1 (en)	2022-11-17	2024-05-23	Bayer Aktiengesellschaft	Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
TW202435917A (zh)	2022-11-17	2024-09-16	美商西雅圖遺傳學公司	Ceacam5抗體-藥物接合物及其使用方法
JP2025541738A (ja)	2022-12-01	2025-12-23	ビオンテック・ソシエタス・エウロパエア	抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
US12534540B2 (en)	2023-01-23	2026-01-27	Clemson University Research Foundation	CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa
WO2024194686A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
CN121620391A (zh)	2023-04-06	2026-03-06	金麦安博股份有限公司	用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
WO2025007862A1 (zh)	2023-07-03	2025-01-09	施慧达药业集团(吉林)有限公司	蛋白质异二聚体的治疗用途
WO2025038750A2 (en)	2023-08-14	2025-02-20	President And Fellows Of Harvard College	Methods and compositions for treating cancer
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
TW202535938A (zh)	2023-10-17	2025-09-16	德商拜恩迪克公司	專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
WO2025147544A1 (en)	2024-01-02	2025-07-10	Abcuro, Inc.	Methods of treating inclusion body myositis (ibm)
WO2025155971A1 (en)	2024-01-19	2025-07-24	Immunomic Therapeutics, Inc	Anti-activin receptor 1c (alk-7) receptor antibodies
TW202545567A (zh)	2024-01-30	2025-12-01	美商思進公司	抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
TW202602929A (zh)	2024-03-21	2026-01-16	美商思進公司	Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
WO2026072990A1 (en)	2024-09-27	2026-04-02	Abcuro, Inc.	Methods of treating t-cell large granular lymphocytic leukemia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en) *	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4172124A (en) *	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
CA1142466A (en) *	1979-01-09	1983-03-08	National Research Development Corporation	Cell lines
US4363799A (en) *	1979-03-20	1982-12-14	Ortho Pharmaceutical Corporation	Monoclonal antibody to human T cells, and methods for preparing same
US4361549A (en) *	1979-04-26	1982-11-30	Ortho Pharmaceutical Corporation	Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4381295A (en) *	1979-04-26	1983-04-26	Ortho Pharmaceutical Corporation	Monoclonal antibody to human helper T cells and methods of preparing same
US4284412A (en) *	1979-07-13	1981-08-18	Ortho Diagnostics, Inc.	Method and apparatus for automated identification and enumeration of specified blood cell subclasses
US4271145A (en) *	1979-10-22	1981-06-02	The Massachusetts General Hospital	Process for producing antibodies to hepatitis virus and cell lines therefor
US4349528A (en) *	1979-11-21	1982-09-14	The Wistar Institute	Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4361544A (en) *	1980-03-03	1982-11-30	Goldenberg Milton David	Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) *	1980-03-03	1982-09-07	Goldenberg Milton David	Tumor localization and therapy with labeled anti-CEA antibody
US4361647A (en) *	1980-05-22	1982-11-30	Palo Alto Medical Research Foundation	Sandwich immunoassay and compositions for use therein
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4359457A (en) *	1980-09-30	1982-11-16	Neville Jr David M	Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
US4356117A (en) *	1980-10-23	1982-10-26	U.S. Govt., Dept. Of Health & Human Services	Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells
US4381292A (en) *	1980-11-14	1983-04-26	The Board Of Trustees Of The Leland Stanford Jr. University	Anti-human T-lymphocyte monoclonal antibody
US4411993A (en) *	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity

1981
- 1981-07-01 US US06/279,248 patent/US4474893A/en not_active Expired - Lifetime
1982
- 1982-06-18 EP EP82303197A patent/EP0068763B2/en not_active Expired - Lifetime
- 1982-06-18 DE DE8282303197T patent/DE3276007D1/de not_active Expired
- 1982-06-18 AT AT82303197T patent/ATE26464T1/de not_active IP Right Cessation
- 1982-06-30 CA CA000406425A patent/CA1190873A/en not_active Expired
- 1982-07-01 JP JP57115320A patent/JPS5859994A/ja active Granted
1991
- 1991-06-10 JP JP3138041A patent/JPH04228067A/ja active Granted
- 1991-06-10 JP JP3138042A patent/JPH084496B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0068763A2 (en)	1983-01-05
JPH0565155B2 (2)	1993-09-17
EP0068763B2 (en)	1993-04-21
EP0068763B1 (en)	1987-04-08
JPH0367678B2 (2)	1991-10-23
CA1190873A (en)	1985-07-23
JPH04228067A (ja)	1992-08-18
JPH04228068A (ja)	1992-08-18
EP0068763A3 (en)	1983-06-08
JPS5859994A (ja)	1983-04-09
JPH084496B2 (ja)	1996-01-24
DE3276007D1 (en)	1987-05-14
US4474893A (en)	1984-10-02

Legal Events

Date	Code	Title	Description
1987-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE26464T1 (de)	1987-04-15	Rekombinante monoklonale antikoerper.
AU577745B2 (en)	1988-09-29	Somatic human hybridoma fusion partner for the production of human monoclonal antibodies
DK7380A (da)	1980-07-10	Cellelinier
MX9203820A (es)	1992-07-01	Ultrapurificacion del factor viii utilizando anticuerpos monoclonales.
BR8102276A (pt)	1982-01-12	Celula de combustivel
SE8300290L (sv)	1983-07-23	Forfarande for framstellning av humana mono-klonala antikroppar
NO153279C (no)	1986-02-12	Elektrokjemisk brennstoffcellekonstruksjon.
DE3372785D1 (en)	1987-09-03	Monoclonal antibodies against lens epithelial cells
DK99682A (da)	1982-03-08	Immunoanalysemetoder under anvendelse af monoklonale antistoffer
EP0113712A4 (en)	1985-09-25	POLYPEPTIDE FRACTION WITH IMMUNOSUPPRESSIVE EFFECT.
DK65185D0 (da)	1985-02-12	Fremgangsmaade til fremstilling af antistof
FI873410L (fi)	1988-02-07	Kahden uuden hybridooman tuottamia apolipoproteiini-B-spesifisiä monoklonaalisia vasta-aineita
NO811640L (no)	1981-11-16	Elektrolysecelle.
GB2083836A (en)	1982-03-31	Monoclonal antibody
NO823098L (no)	1982-09-13	Anodetappedekk for elektrolyttceller.
DE3579009D1 (de)	1990-09-13	Adult-t-zell-leukemiavirus-antigenpolypeptid.
ES8505409A1 (es)	1985-05-16	Procedimiento para purificar interferon de humano
DK188185D0 (da)	1985-04-26	Monoklonalt antistof
DK143477A (da)	1977-10-03	Fremgangsmade til dyrkning af celler
IL68752A (en)	1989-06-30	Human hybridomas cell lines producing monoclonal antibodies capable of distinguishing neoplastic cells from normal cells,antibodies produced by them and method for determining the presence of a neoplasm by using said antibodies
DE3586808D1 (de)	1992-12-17	L-thyroxin erkennende monoklonale antikoerper.
DK144485D0 (da)	1985-03-29	Monoklonale antistoffer
DK37382A (da)	1982-07-29	Fremgangsmaade til fremstilling af hybridceller,der producereret antistof,fremgangsmaade til fremstilling af antistoffer samt hybridceller og antistoffer
AU560262B2 (en)	1987-04-02	Antibodies derived from hybrid line from (myeloma + antibody producing cell)
IL82972A (en)	1991-06-30	Fused hybrid cell from mammalian or plant cells said fusion being facilitated by agglutination